Trial Profile
Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms FRAIL-IMMUNE
- 19 Apr 2024 Status changed from recruiting to completed.
- 06 Jun 2023 Results (n=64) reporting safety and efficacy data at 18 months presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 03 Oct 2022 Planned End Date changed from 1 Feb 2024 to 1 Aug 2024.